Introduction
N-linked glycosylation is initiated by the cotranslational transfer of a 14-residue oligosaccharide precursor (Glc3MangGlcNAc2) to certain polypeptides that contain the Asn-XaaSer/Thr glycosylation sequon [ 13. After transfer the glycan chain is modified by a series of reactions within the endoplasmic reticulum (ER) and Golgi apparatus (Figure 1 ). The first processing event is the step-wise removal of the terminal glucose residues by the ER a-glucosidases. a-Glucosidase I removes the outer a 1 &linked glucose residue while the inner two a 1,3-1inked glucose residues are removed in two steps by a-glucosidase 11. In contrast with many of the Abbreviations used: ER, endoplasmic reticulum; MDCK, Madin-Derby canine kidney; NB-DNJ, N-butyldeoqnojirimycin; DMJ, deoqmanojirimycin; HBV, hepatitis B virus; VSV, vesicular stomatitis virus; HIV, human immunodeficiency virus; HA, haemagglutinin.
other glycan-processing events in the secretory pathway, the removal of the glucose residues is highly efficient. Cells do not normally secrete glycoproteins containing glucosylated glycan structures. Indeed, many cell types contain an additional pathway, the Golgi-endomannosidase pathway, that can remove glucose residues from glycoproteins that have not been fully processed within the ER [2] . In the absence of a-glucosidase inhibitors, this pathway can allow further Golgi processing events to occur.
ER glucosidase processing allom interactions with chaperone proteins
T h e glucosidase reactions allow glycoproteins to interact with the ER chaperones calnexin and calreticulin [3] . Recent work has determined that calnexin (which is membrane bound) and calreticulin (which is soluble) are lectins that bind exclusively to monoglucosylated glycoproteins independent of protein conformation (Figure 2; [4]). Monoglucosylated glycoproteins can be Some of the major processing events in the biosynthesis of N-linked glycans N-linked glycosylation is initiated by the transfer of a 14-sugar superstructure to the growing polypeptide co-translationally, The formation of this superstructure can be inhibited by the tunicamycin (not shown). Other inhibitors of glycan-processing events are shown in boxes. After transfer to the Golgi, reactions can terminate at several steps, leading to the secretion of differentially glycosylated proteins (glycoforms). The three major classes of N-linked glycans are shown at the bottom (complex, hybrid and oligomannose [26] . A, glucose residues. . This process allows further interactions with calnexin to occur, and can continue until the native conformation of the protein is achieved and the glycoprotein is no longer re-glucosylated by the glucosyltransferase. For some proteins, such as vesicular stomatitis virus (VSV) G protein and influenza virus haemagglutinin (HA), preventing a calnexin interaction with inhibitors of the a-glucosidase causes their misfolding and prolonged retention within the ER [7] . As not all proteins require a calnexin pathway to achieve their native conformation, inhibitors of the a-glucosidases can be used to target specifically the folding of proteins which require an interaction with calnexin.
Modifications in the Golgi lead to structural diversification of glycans on glycoproteins
Transport through the Golgi leads to further trimming events and the subsequent elongation of the glycan chain [l] . Factors that control the glycan processing in the Golgi include the concentration of the glycan-processing enzymes within a particular cell (cell-specific glycosylation), and the accessibility of those enzymes to the glycan chain (site-specific glycosylation). Although all proteins that enter the secretory pathway in a given cell are exposed to the same glycosylation machinery, most emerge from the Golgi as a heterogeneous mixture of glycoforms in which a single polypeptide chain contains a range of sugars at each glycosylation site. Glycoforms arise from incomplete glycan-processing events and enzyme competition for the same substrate. An example of this is the cell-surface marker CD59, which has over 100 different glycoforms associated with a single site of N-glycan attachment [8] .
Within a given cell, the local three-dimensional structure of the glycoprotein can affect the glycan processing at each glycosylation site. An example of this is the site-specific glycosylation of influenza virus HA expressed in Madin-Derby canine kidney (MDCK) cells. Influenza virus HA (strain A/WSN/33) contains four sites of N-linked glycosylation. In MDCK cells three of these sites (Asn-21, -129 and -271) are fully processed to the complex type. In contrast, site Asn-65 contains only oligomannose glycan structures (Figure 3 ; [9] ). 
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ing enzymes to this site, which is buried within a proteins. These glycoproteins are often essential cleft in the HA monomer and completely covered proteins in that they are required in the viral life in the HA homotrimer which forms in the ER cycle, either in virion assembly and secretion and intermediate compartment [9] . and/or infectivity. As processing of these glycoproteins occurs through the cellular machinery,
Glycosylat ion in hi bitors as anti-viral
inhibitors of the N-glycan-processing pathway agents have been used to study the role of the N-glycans Many animal viruses contain an outer envelope in several viral systems including human which is composed of one or more viral glycoimmunodeficiency virus (HIV-1; Figure 3 Site-specific glycosylation of the influenza virus HA monomer [15] . Two examples that highlight N-linked glycan processing as a target of anti-viral intervention are the HIV model and the HBV model.
Glucosidase inhibitors prevent the secretion of infectious HIV
HIV-1, the causative agent of acquired immunodeficiency syndrome, encodes two essential envelope glycoproteins (gp120 and gp41) through endoproteolytic cleavage of a precursor protein (gp160) within the cis-Golgi apparatus. Although proteolytically cleaved, gp 120 remains noncovalently attached to the lumenal portion of the transmembrane gp41 through two conserved regions in both the N-and C-terminus. Therefore, on the viral envelope, gp120 is fully exposed (outside the viral envelope), with the transmembrane gp41 acting as an anchor for the complex [16] . During infection, gp120 binds to the CD4 surface antigen (the cellular receptor) and undergoes a conformational change that exposes gp41. The exposure of gp41 allows fusion with the cellular membrane, thus mediating viral entry into the cell [17] . Both of these proteins are heavily N-glycosylated and normally contain a mixture of complex and oligomannose-type glycans [ 161. Treatment of HIV-1-infected cells with N-butyldeoxynojirimycin (NB-DNJ), an inhibitor of the a-glucosidases, inhibits syncytium formation and the formation of infectious virus [18] . In contrast, the mannosidase inhibitor deoxymanojirimycin (DMJ, see Figure 1 ) had no effect on the secretion of infectious virus, suggesting that ER processing by glucosidase was required for correct interactions with calnexin and/or calrecticulin [ 11.
The reduction in secretion of infectious virus caused by NB-DNJ is the result of impairments in post-CD4 binding steps [19] . Although binding to CD4 occurs, the conformational shift in gp120 that exposes gp41 does not; thus viral fusion is prevented. Consistent with this, is the finding that in the presence of NB-DNJ there is regional misfolding of gp120. Analysis of gp120 by a panel of conformation-dependent antibodies revealed structural changes only within the V1 /V2 loop region [ZO] . This indicates that the V1/V2 domains require ER processing of the glucose residues and suggests that only these regions fold through a calnexin/calreticulin-dependent pathway. Although this does not prevent the transport of gp120 to the plasma membrane, or viral budding, these misfoldings are sufficient to inhibit the viral fusion process, a crucial step in the HIV life cycle. 
HBV
In contrast to the HIV envelope glycoproteins, which contain 30 sites of N-linked glycosylation [16] , the envelope proteins of HBV contain only two glycosylation sites. However, just as with the HIV envelope proteins, these are sensitive to inhibitors of the N-linked glycosylation pathway. HBV, which infects over 350 million people worldwide, is a major aetiological agent of liver disease and hepatocellular carcinoma [21] . The HBV genome encodes for three envelope proteins: large (L), middle (M) and small (S).
These are derived from a single open reading frame by the use of alternative translational start sites (see Figure 4; [ZZ]). In addition to being the major component of the viral envelope, these proteins are secreted in the form of smaller noninfectious subviral particles. These particles, which lack DNA, are secreted in vast excess compared with the viral particle.
T h e role of the N-glycans of HBV has been probed with site-directed mutagenesis and inhibitors of the N-linked glycosylation pathway. These includes tunicamycin (an inhibitor of N-linked glycosylation; [23] ), NB-DNJ [ 113 and DMJ [23] . These results are summarized in Table 1 .
Treatment of an HBV-secreting cell line (Hep G2.2.15) with NB-DNJ prevents the secretion of enveloped DNA [15] and causes the intracellular accumulation of viral DNA and particles containing the M protein [24] . In contrast, subviral particles containing the L and S proteins are secreted and contain a full array of complex glycan structures that have been processed through the Golgi-endomannosidase pathway. In the presence of the glucosidase blockade, the Golgi-endomannosidase will remove all three glucose residues in one step [Z] , suggesting that both ER glucose processing and interactions with chaperones like calnexin (which only recognize monoglucosylated glycoproteins) are not required for the correct folding of the S or L proteins.
This finding also implies that the Golgi-endo-
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mannosidase pathway may only process fully folded glycoproteins.
Unlike many proteins that are retained by glucosidase inhibition, retained M protein is not rapidly degraded but forms large particles with half-lives in excess of 24 h [25] . Moreover these Figure 4 Hepatitis B envelope glycoproteins (a) the HBV envelope proteins. The L protein consists of three domains: the pre-SI domain, pre-S2 domain and the S domain. M contains the pre-S2 and S domains, whereas the S protein contains only the S domain. All three proteins have a common N-linked glycosylation site N at Asn-I46 of the S domain with the M protein containing an additional site at Asn-4 of the pre-S2 domain. The S glycan site is partially occupied in all three envelope proteins, whereas the pre-S2 site is fully occupied in M [22] . The L protein, while containing the pre-S2 glycosylation sequon, only uses the shared S glycan site [22] . (b) aberrant M particles leave the ER and enter the Golgi apparatus. However, instead of being secreted, a large proportion are returned to the ER and eventually targeted to lysosomal vesicles for destruction. This 'retrograde' transport of the M protein is analogous to the recycling of misfolded VSV 'G' protein [26] . In VSV G protein, the retrieval is mediated by binding to Bip, an ER resident chaperone which contains an ER localization signal. Site-directed mutagenesis provides evidence that the pre-S2 glycosylation site on M protein plays an important role in virion morphogenesis [24] . Viral glycoproteins that lacked the pre-S2 glycan site (Mg-) were unable to secrete virus. In contrast, removal of the common site in the S domain (Sg-) had no effect on viral secretion. These results, in conjunction with those seen in Table 1 , indicate that the proper folding of the M protein requires the processing of the pre-S2 glycan to a GlclMan9GlcNAcz structure. This allows the pre-S2 glycan on M protein to interact with calnexin. When this monoglucosylated structure is prevented from being formed, either by site-directed mutagenesis, tunicamycin, or NB-DNJ, the M protein misfolds and viral envelopment is prevented. Consistent with this is the effect of DMJ, a mannosidase inhibitor that prevents the formation of complex glycan structures, but does not interfere with the removal of the terminal glucose residues (Table 1) . T h e importance of glycosylation in the pre-S2 domain of M protein is consistent with the full occupancy of this site, as opposed to the variable occupancy of the glycan sequon in the S domain. The finding that the inhibition of glycan processing of a single site can so profoundly influence HBV secretion provides a powerful target for anti-viral intervention.
Conclusion
T h e process of N-linked glycosylation is a dynamic event that plays many roles in the fate and function of proteins. One function is assisting protein folding through interactions with lectin-like chaperones in the ER. In HIV and HBV, the prevention of these interactions can interfere with the viral life cycle. Indeed, in a woodchuck model of HBV, treatment with glucosidase inhibitors has been shown to reduce the secretion of enveloped virus. Thus the concept of using inhibitors of the glycan-processing pathway to interfere with protein folding may provide a
